American Health Packaging is voluntarily recalling one lot of Valsartan Tablets, USP, 160 mg to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product.
The impurity detected in the finished drug product is N-Nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. This recall is being initiated in response to the recall by the manufacturer (Aurobindo Pharma USA, Inc.), which included the affected lot that was repackaged by American Health Packaging.
Valsartan Tablets USP are indicated to control high blood pressure and for the treatment of heart failure. Patients who prescribed Valsartan Tablets USP should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.
Product was distributed Nationwide to Wholesalers for use in hospital settings. No reports of injury or adverse events to date.
American Health Packaging is notifying its distributors by recall letter sent March 6, 2019 and to immediately discontinue distribution of the specific lots being recalled and to notify their sub- accounts. American Health Packaging is arranging for return of all recalled products to GENCO Pharmaceutical Services. Instructions for returning recalled products are given in the recall letter. Pharmacies that have received the affected lot should contact any patients who may have received the recall lots and have them call (877) 475-5864 to receive a return packet. Consumers should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.
Consumers with medical questions regarding this recall or to report an adverse event can contact Aurobindo Pharma USA, Inc. at:
On Monday, Los Angeles County Public Health officials confirmed that the State and L.A. County will be keeping the current masking guidance until June 15 to remain in alignment with the L.A. County Health Officer Order of May 3.
Los Angeles police have arrested a man suspected of igniting a wildfire that has so far burned over 1,300 acres and spurred mandatory evacuations as fire crews battled the blaze in steep, brush-filled terrain in a canyon community west of the city.
A new report published by the Los Angeles County Department of Arts and Culture and Claremont Graduate University’s Center for Business and Management of the Arts revealed disparities between earnings of L.A. County arts administrators that identify as Black, Indigenous, and People of Color and their White counterparts.
Gov. Gavin Newsom unveiled a plan that would spend about $1.5 billion of the state’s $75.7 billion surplus in grants of up to $25,000 to support small businesses, according to state officials this week.
Fourteen-year-old Andrew Jenofsky was the first in line to get his shot at Henry Mayo Newhall Hospital Thursday morning, as adolescents ages 12-15 were given the go-ahead to get Pfizer’s COVID-19 vaccine.
Los Angeles County Public Health officials said it will review the Centers for Disease Control and Prevention's newly released guidance for fully vaccinated residents in order to make adjustments to the current County and state guidelines.